Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion type Assertion NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_head.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion description "[Therefore, the development of small molecule inhibitors of BCL2A1 may be a promising approach mainly to sensitize tumor cells for apoptosis and thus improve the efficiency of anti-cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_provenance.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion evidence source_evidence_literature NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_provenance.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion SIO_000772 22075983 NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_provenance.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion wasDerivedFrom befree-20150227 NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_provenance.
- NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_assertion wasGeneratedBy ECO_0000203 NP264198.RAFzjTD72u8YXOotA0afXndd18EgBUJkb-2bGa93pd5_I130_provenance.